{
    "nctId": "NCT00127205",
    "briefTitle": "S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.",
    "officialTitle": "Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6097,
    "primaryOutcomeMeasure": "Disease-free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary adenocarcinoma of the breast\n\n  * Stage I-III disease\n  * No evidence of metastatic disease\n* Must have undergone lumpectomy or total mastectomy for primary disease within the past 12 weeks, or have completed chemotherapy within the past 8 weeks\n\n  * Axillary evaluation per institutional standards\n* Currently receiving or planning to receive standard adjuvant systemic therapy comprising chemotherapy, hormonal therapy, or combined chemotherapy/hormonal therapy for breast cancer\n\n  * Patients who are at low risk for disease recurrence and for whom adjuvant systemic therapy will not be prescribed are not eligible\n  * Patients who receive biologic agents only or local radiotherapy only (without chemotherapy and/or hormone therapy) are not eligible\n  * Additional therapies are allowed including radiotherapy and biologic agents (e.g., trastuzumab \\[Herceptin\\^\u00ae\\], bevacizumab, or hematopoietic growth factors)\n  * Neoadjuvant therapy or hormonal therapy alone is allowed provided study entry occurs \u2265 12 weeks after completion of surgery\n* Patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease\n\n  * Suspicious findings must be confirmed as benign by x-ray, MRI, or biopsy\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Creatinine \u2264 2 times upper limit of normal\n* Creatinine clearance \u2265 30 mL/min\n* No renal failure\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No history of esophageal stricture or motility disorders\n\n  * Gastroesophageal reflux disorder allowed\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior or concurrent hematopoietic growth factors allowed\n* HER-2-targeted therapies allowed\n* Antiangiogenics allowed\n\nChemotherapy\n\n* See Disease Characteristics\n\nEndocrine therapy\n\n* See Disease Characteristics\n\nRadiotherapy\n\n* Concurrent radiotherapy to the breast, chest wall, or lymph node group allowed at the discretion of the treating physician\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* Prior neoadjuvant therapy allowed\n* Prior bisphosphonates for bone density allowed\n* No other concurrent bisphosphonates as adjuvant therapy or for treatment of osteoporosis\n* No concurrent enrollment in clinical trials with bone density as an endpoint\n\n  * Concurrent enrollment on any other locoregional or systemic therapy breast cancer study (including cooperative group studies) allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}